Advertisement

Challenges in Cervical Cancer Prevention

A Survey of U.S. Obstetrician-Gynecologists

      Background

      Current cervical cancer prevention recommendations include human papillomavirus (HPV) vaccination, Pap and HPV co-testing, and Pap testing at 3- to 5-year intervals.

      Purpose

      To examine attitudes, practice patterns, and barriers related to HPV vaccination and cervical cancer screening guidelines among U.S. obstetrician-gynecologists.

      Methods

      In 2011–2012, a national sample of members of the American Congress of Obstetricians and Gynecologists responded to a 15-item (some with multiple parts) questionnaire assessing sociodemographic characteristics, clinical practices, and perceived barriers to HPV vaccination and cervical cancer screening. Multivariate logistic regression was used to identify factors associated with guideline adherence. Analyses were conducted in 2012.

      Results

      A total of 366 obstetrician-gynecologists participated. Ninety-two percent of respondents offered HPV vaccination to patients, but only 27% estimated that most eligible patients received vaccination. Parent and patient refusals were commonly cited barriers to HPV vaccination. Approximately half of respondents followed guidelines to begin cervical cancer screening at age 21 years, discontinue screening at age 70 years or after hysterectomy, and appropriately utilize Pap and HPV co-testing. Most physicians continued to recommend annual Paps (74% aged 21–29 years, 53% aged ≥30 years). Physicians felt that patients were uncomfortable with extended screening intervals and were concerned that patients would not come for annual exams without concurrent Paps. Solo practitioners were less likely to follow both vaccination and screening guidelines than those in group practices.

      Conclusions

      This survey of obstetrician-gynecologists indicates persistent barriers to the adoption of HPV vaccination and cervical cancer screening guidelines. Interventions to promote guideline adherence may help improve the quality of cervical cancer prevention.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • ACOG
        Human papillomavirus vaccination.
        Committee Opinion. 2010; (Number 467)
        • ACIP
        Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Comitte on Immunization Practices.
        MMWR Morbidity and Mortality Weekly Report. 2007; 56
        • ACOG
        Cervical cytology screening.
        Practice Bulletin. 2009; (Number 109)
        • Saslow D.
        • Solomon D.
        • Lawson H.W.
        • et al.
        American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
        Am J Clin Pathol. 2012; 137: 516-542
        • Leddy M.A.
        • Anderson B.L.
        • Gall S.
        • Schulkin J.
        Obstetrician-gynecologists and the HPV vaccine: practice patterns, beliefs, and knowledge.
        J Pediatr Adolesc Gynecol. 2009; 22: 239-246
        • Hirth J.M.
        • Tan A.
        • Wilkinson G.S.
        • Berenson A.B.
        Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009.
        Cancer. 2012; 118: 5623-5629
        • Lee J.W.
        • Berkowitz Z.
        • Saraiya M.
        Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers.
        Obstet Gynecol. 2011; 118: 4-13
        • Saraiya M.
        • Berkowitz Z.
        • Yabroff K.R.
        • Wideroff L.
        • Kobrin S.
        • Benard V.
        Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?.
        Arch Intern Med. 2010; 170: 977-985
      1. Sheinfeld Gorin S, Westhoff C, NYPAC. The HPV vaccine: a promising intervetnion approach to increase dissemination. Oral presentation, Society of Behavioral Medicine Annual Meeting; Apr 10, 2010; Seattle WA.

        • Brewer N.T.
        • Fazekas K.I.
        Predictors of HPV vaccine acceptability: a theory-informed, systematic review.
        Prev Med. 2007; 45: 107-114
        • Raley J.C.
        • Followwill K.A.
        • Zimet G.D.
        • Ault K.A.
        Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists.
        Infect Dis Obstet Gynecol. 2004; 12: 127-133
        • Kahn J.A.
        • Cooper H.P.
        • Vadaparampil S.T.
        • et al.
        Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians.
        Cancer Epidemiol Biomarkers Prev. 2009; 18: 2325-2332
        • Sheinfeld Gorin S.N.
        • Glenn B.A.
        • Perkins R.B.
        The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps.
        Adv Ther. 2011; 28: 615-639
        • Perkins R.B.
        • Clark J.A.
        What affects human papillomavirus vaccination rates? A qualitative analysis of providers' perceptions.
        Womens Health Issues. 2012; 22: e379-e386
        • Meissner H.I.
        • Tiro J.A.
        • Yabroff K.R.
        • Haggstrom D.A.
        • Coughlin S.S.
        Too much of a good thing? Physician practices and patient willingness for less frequent pap test screening intervals.
        Med Care. 2010; 48: 249-259
        • Ashok M.
        • Berkowitz Z.
        • Hawkins N.A.
        • Tangka F.
        • Saraiya M.
        Recency of Pap testing and future testing plans among women aged 18-64: analysis of the 2007 Health Information National Trends Survey.
        J Womens Health (Larchmt). 2012; 21: 705-712
        • Roland K.B.
        • Soman A.
        • Benard V.B.
        • Saraiya M.
        Human papillomavirus and Papanicolaou tests screening interval recommendations in the U.S.
        Am J Obstet Gynecol. 2011; 205: e1-e8
        • Power M.L.
        • Leddy M.A.
        • Anderson B.L.
        • Gall S.A.
        • Gonik B.
        • Schulkin J.
        Obstetrician-gynecologists' practices and perceived knowledge regarding immunization.
        Am J Prev Med. 2009; 37: 231-234
      2. Census. Overview of Race and Hispanic Origin: 2010. wwwcensusgov/prod/cen2010/briefs/c2010br-02pdf. 2010.

        • Brotherton J.M.
        • Fridman M.
        • May C.L.
        • Chappell G.
        • Saville A.M.
        • Gertig D.M.
        Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.
        Lancet. 2011; 377: 2085-2092
        • Read T.R.
        • Hocking J.S.
        • Chen M.Y.
        • Donovan B.
        • Bradshaw C.S.
        • Fairley C.K.
        The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.
        Sex Transm Infect. 2011; 87: 544-547
        • Eaton D.K.
        • Kann L.
        • Kinchen S.
        • et al.
        Youth risk behavior surveillance—U.S., 2011.
        MMWR Surveill Summ. 2012; 61: 1-162
        • Dillner J.
        • Rebolj M.
        • Birembaut P.
        • et al.
        Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
        BMJ. 2008; 337: a1754
        • Katki H.A.
        • Kinney W.K.
        • Fetterman B.
        • et al.
        Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
        Lancet Oncol. 2011; 12: 663-672
        • Bartlett J.A.
        • Peterson J.A.
        The uptake of human papillomavirus (HPV) vaccine among adolescent females in the U.S.: a review of the literature.
        J Sch Nurs. 2011; 27: 434-446
        • Dorell C.G.
        • Yankey D.
        • Santibanez T.A.
        • Markowitz L.E.
        Human papillomavirus vaccination series initiation and completion, 2008-2009.
        Pediatrics. 2011; 128: 830-839
        • Guerry S.L.
        • De Rosa C.J.
        • Markowitz L.E.
        • et al.
        Human papillomavirus vaccine initiation among adolescent girls in high-risk communities.
        Vaccine. 2011; 29: 2235-2241
        • Rosenthal S.L.
        • Weiss T.W.
        • Zimet G.D.
        • Ma L.
        • Good M.B.
        • Vichnin M.D.
        Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation.
        Vaccine. 2010; 29: 890-895
        • Becker H.I.
        • Longacre M.R.
        • Harper D.M.
        Beyond the Pap: assessing patients' priorities for the annual examination.
        J Womens Health (Larchmt). 2004; 13: 791-798
        • Kissin D.M.
        • Power M.L.
        • Kahn E.B.
        • et al.
        Attitudes and practices of obstetrician-gynecologists regarding influenza vaccination in pregnancy.
        Obstet Gynecol. 2011; 118: 1074-1080
        • Brooks S.E.
        • Chen T.T.
        • Ghosh A.
        • Mullins C.D.
        • Gardner J.F.
        • Baquet C.R.
        Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix.
        Gynecol Oncol. 2000; 79: 107-115
        • Akers A.Y.
        • Newmann S.J.
        • Smith J.S.
        Factors underlying disparities in cervical cancer incidence, screening, and treatment in the U.S.
        Curr Probl Cancer. 2007; 31: 157-181
        • Flocke S.A.
        • Gilchrist V.
        Physician and patient gender concordance and the delivery of comprehensive clinical preventive services.
        Med Care. 2005; 43: 486-492
        • Fisher E.S.
        • Wennberg D.E.
        • Stukel T.A.
        • Gottlieb D.J.
        • Lucas F.L.
        • Pinder E.L.
        The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care.
        Ann Intern Med. 2003; 138: 288-298
        • Fisher E.S.
        • Wennberg D.E.
        • Stukel T.A.
        • Gottlieb D.J.
        • Lucas F.L.
        • Pinder E.L.
        The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care.
        Ann Intern Med. 2003; 138: 273-287
        • Clark S.L.
        • Belfort M.A.
        • Hankins G.D.
        • Meyers J.A.
        • Houser F.M.
        Variation in the rates of operative delivery in the U.S.
        Am J Obstet Gynecol. 2007; 196: e1-e5
      3. The Dartmouth Atlas of Healthcare. 2012. http://www.dartmouthatlas.org/keyissues/issue.aspx?con=2939.

        • Wei F.
        • Moore P.C.
        • Green A.L.
        Geographic variability in human papillomavirus vaccination among U.S. young women.
        Am J Prev Med. 2013; 44: 154-157
      4. Gordon N. How does the adult Kaiser Permanente membership in Northern California compare with the Larger Community? www.dor.kaiser.org/external/uploadedFiles/content/research/mhs/_2011_Revised_Site/Documents_Special_Reports/comparison_kaiser_vs_nonKaiser_adults_kpnc(1).pdf. 2006.

        • Pilote L.
        • Califf R.M.
        • Sapp S.
        • et al.
        Regional variation across the U.S. in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
        N Engl J Med. 1995; 333: 565-572
      5. SEER. SEER stat fact sheets: cervix uteri. Incidence & mortality seer.cancer.gov/statfacts/html/cervix.html - incidence-mortality.

        • Davis T.C.
        • Williams M.V.
        • Marin E.
        • Parker R.M.
        • Glass J.
        Health literacy and cancer communication.
        CA Cancer J Clin. 2002; 52: 134-149
        • Sabatino S.A.
        • Lawrence B.
        • Elder R.
        • et al.
        Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services.
        Am J Prev Med. 2012; 43: 97-118

      Linked Article